everolimus zentiva 10 mg
genepharm s.a. - grecia - everolimus - compr. - 10 mg - inhibitori de protein-kinaza inhibitor selectiv al mtor
everolimus zentiva 2,5 mg
genepharm s.a. - grecia - everolimus - compr. - 2,5 mg - inhibitori de protein-kinaza inhibitor selectiv al mtor
everolimus zentiva 5 mg
genepharm s.a. - grecia - everolimus - compr. - 5 mg - inhibitori de protein-kinaza inhibitor selectiv al mtor
sunitinib viatris 12,5 mg
remedica ltd - cipru - sunitinibum - caps. - 12,5mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
sunitinib viatris 25 mg
remedica ltd - cipru - sunitinibum - caps. - 25mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
sunitinib viatris 37,5 mg
remedica ltd - cipru - sunitinibum - caps. - 37,5mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
sunitinib viatris 50 mg
remedica ltd - cipru - sunitinibum - caps. - 50mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
eufrenin 50 mg
lek pharmaceuticals d.d. - slovenia - quetiapinum - compr. cu elib. prel. - 50mg - antipsihotice diazepine, oxazepine si tiazepine
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - agenți antineoplazici - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
quetiapina accord 200 mg
accord healthcare limited - quetiapinum - compr. cu elib. prel. - 200mg - antipsihotice diazepine, oxazepine si tiazepine